Clinical Trials
2.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1874 trials with phase data)• Click on a phase to view related trials
Microbiome and Atopy in Mali
- Conditions
- Atopic Disease
- First Posted Date
- 2025-07-04
- Last Posted Date
- 2025-07-04
- Target Recruit Count
- 288
- Registration Number
- NCT07051902
- Locations
- 🇲🇱
Dermatology Hospital of Bamako, Bamako, Mali
🇲🇱Pneumology Ward, Point G University Hospital, Bamako, Mali
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Target Recruit Count
- 30
- Registration Number
- NCT07040319
- Locations
- 🇺🇸
USC LA, Los Angeles, California, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
- Conditions
- DysphagiaEosinophilic Esophagitis
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-07-10
- Target Recruit Count
- 70
- Registration Number
- NCT07027826
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇲🇱Gabriel Toure University Hospital Center, Bamako, Mali
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
- Conditions
- Avian Influenza
- Interventions
- Biological: H5 AC-Anhui RNA VaccineBiological: H5 Astrakhan RNA VaccineOther: Sodium Chloride, 0.9%
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-27
- Target Recruit Count
- 80
- Registration Number
- NCT07019883
- Locations
- 🇺🇸
Duke Vaccine and Trials Unit, Durham, North Carolina, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
- Conditions
- Peanut Allergy
- Interventions
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-18
- Target Recruit Count
- 62
- Registration Number
- NCT07015996
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology, Little Rock, Arkansas, United States
🇺🇸University of California, Los Angeles: Department of Medicine, Division of Clinical Immunology and Allergy, Los Angeles, California, United States
🇺🇸Johns Hopkins Children's Center: Department of Allergy & Immunology, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 481
- Next
News
Saint Louis University Launches Phase 1 Trial for Investigational West Nile Virus Vaccine
Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine.
HHS and NIH Launch "Generation Gold Standard" Universal Vaccine Platform to Combat Pandemic Threats
The U.S. Department of Health and Human Services and NIH have announced "Generation Gold Standard," a next-generation universal vaccine platform using beta-propiolactone-inactivated whole-virus technology.
Three Pharmaceutical Companies Advance Next-Generation COVID-19 Therapeutics in Clinical Trials
INOVIO Pharmaceuticals reports promising Phase I results for its DMAbs technology, showing 100% of subjects maintained relevant antibody levels with no serious adverse events.
NIH Launches First Clinical Trial of Moderna's mRNA Vaccine Against Deadly Nipah Virus
The National Institutes of Health has initiated the first human trial of Moderna's mRNA-1215 vaccine targeting Nipah virus, a deadly pathogen with a 40-70% fatality rate.
HIV Cure Trials at CROI 2025 Show Promise for Broader Patient Applications
At the 2025 Conference on Retroviruses and Opportunistic Infections (CROI), researchers presented promising results from multiple HIV cure trials, suggesting potential for wider therapeutic applications.
NIH Launches First Human Trial of LASSARAB Vaccine for Deadly Lassa Fever
The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients.
Corvus Pharmaceuticals Initiates Phase 2 Trial of Soquelitinib for Rare Genetic Disease ALPS
NIH/NIAID has launched a Phase 2 clinical trial of Corvus Pharmaceuticals' soquelitinib for autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease typically manifesting by age two.
Kenox and Lactiga Partner to Develop First-in-Class Mucosal Immunotherapy for Immunodeficient Patients
Kenox Pharmaceuticals and Lactiga have formed a strategic collaboration to develop novel secretory IgA (sIgA) therapies for immunodeficient patients, supported by a multi-million-dollar NIAID grant.
mRNA Vaccines Show Promise as H5N1 Avian Influenza Cases Rise in US Cattle and Humans
The US is experiencing a significant H5N1 avian influenza outbreak affecting over 800 dairy herds across 16 states, with 66 confirmed human cases and one death reported in early 2025.
Xolair Receives FDA Approval for Food Allergies After Two Decades
Xolair, initially approved for asthma in 2003, has now been FDA-approved for treating food allergies, offering relief to millions with severe allergic reactions.